Preexisting Insulin Autoantibodies Predict Efficacy of Otelixizumab in Preserving Residual β-Cell Function in Recent-Onset Type 1 Diabetes

OBJECTIVE: Immune intervention trials in recent-onset type 1 diabetes would benefit from biomarkers associated with good therapeutic response. In the previously reported randomized placebo-controlled anti-CD3 study (otelixizumab; GlaxoSmithKline), we tested the hypothesis that specific diabetes auto...

Descripción completa

Detalles Bibliográficos
Autores principales: Demeester, Simke, Keymeulen, Bart, Kaufman, Leonard, Van Dalem, Annelien, Balti, Eric V., Van de Velde, Ursule, Goubert, Patrick, Verhaeghen, Katrijn, Davidson, Howard W., Wenzlau, Janet M., Weets, Ilse, Pipeleers, Daniel G., Gorus, Frans K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2015
Materias:
Emerging Technologies and Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4370324/
https://www.ncbi.nlm.nih.gov/pubmed/25583753
http://dx.doi.org/10.2337/dc14-1575

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4370324/
https://www.ncbi.nlm.nih.gov/pubmed/25583753
http://dx.doi.org/10.2337/dc14-1575

Ejemplares similares